Completed phase I/IIa clinical trial
Twenty-seven patients participated in phase I/IIa clinical trials conducted in 4 clinical centers in Russia.
High degree of safety was demonstrated in dose escalation studies.
Three groups, of five
patients each, were administered escalating doses of Elenagen™. Only minimal
Grade I side effects were observed in some patients.
Elenagen™ was able to cease disease progression
in patients with breast, ovary, lung, renal cancer and melanoma. Patients
admitted into our trial were “salvage patients” who have failed all other available
treatment protocols and were in the active disease progression stage. The main
goal was to stop the disease progression, which we have achieved.
Restoring tumor sensitivity to chemotherapy.
All patients admitted to the clinical
trials have already failed multiple lines of chemotherapy. However, after
treatment with Elenagen™, the
patients were able to succesfully respond to new rounds of chemotherapy.
Future Phase II clinical trials
CureLab Oncology, Inc. is planning to conduct US and international phase II clinical trials in following diseases:
Metastatic breast Cancer
Metastatic hormone-resistant prostate cancer
Metastatic renal cancer
Metastatic uterus cancer